Curated News
By: NewsRamp Editorial Staff
July 15, 2026
Kairos Pharma ENV-105 Shows Favorable Safety in Lung Cancer Trial
TLDR
- Kairos Pharma's ENV-105 shows no severe side effects, potentially restoring osimertinib efficacy and extending market advantage in NSCLC.
- ENV-105 targets CD105 to reverse drug resistance, combined with osimertinib in a Phase 1 trial with manageable side effects.
- This therapy aims to improve outcomes for lung cancer patients who have limited options after resistance develops.
- ENV-105 targets CD105, a protein linked to drug resistance, offering a novel approach to combat cancer relapse.
Impact - Why it Matters
This news matters because it offers hope for patients with EGFR-mutated non-small cell lung cancer who have developed resistance to osimertinib, the current standard of care. If ENV-105 proves effective, it could significantly extend the duration of benefit from osimertinib, providing an additional treatment option and potentially improving survival outcomes in a patient population with limited alternatives.
Summary
Kairos Pharma (NYSE American: KAPA) announced favorable interim safety results from its ongoing Phase 1 trial evaluating ENV-105 (carotuximab) in combination with osimertinib (Tagrisso) for patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC) who have developed resistance to osimertinib. The company reported no Grade 3 or higher treatment-related adverse events among 13 patients treated with ENV-105 to date, supporting continued advancement of the program toward an early efficacy readout. ENV-105 is designed to inhibit CD105, a protein associated with acquired drug resistance, with the goal of restoring sensitivity to osimertinib.
Kairos said the Phase 1 study is evaluating the safety, tolerability and recommended Phase 2 dose of the combination therapy, with all reported side effects manageable through standard supportive care. The company believes ENV-105 has the potential to extend the clinical utility of osimertinib, the current standard of care for EGFR-mutated NSCLC, by addressing acquired resistance after disease progression. Based in Los Angeles, California, Kairos Pharma is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. ENV-105 is also in a Phase 2 trial for castrate-resistant prostate cancer.
This news was disseminated by BioMedWire, a specialized communications platform with a focus on the latest developments in the biotechnology, biomedical sciences, and life sciences sectors. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which delivers a vast network of wire solutions and editorial syndication to 5,000+ outlets. For more information, visit BioMedWire.com.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Kairos Pharma ENV-105 Shows Favorable Safety in Lung Cancer Trial
